Apixaban to prevent venous thromboembolism after knee replacement

The Lancet

Volumn 375, Issue 9717, 2010, Pages 779-780

  Fareed, Jawed ^a   Hull, Russell ^b  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; RIVAROXABAN; THROMBIN;

ANTICOAGULATION; ARTICLE; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FOOD; HIP ARTHROPLASTY; HUMAN; LONG TERM CARE; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; LUNG VENTILATION PERFUSION RATIO; MORTALITY; ORTHOPEDIC SURGERY; PHLEBOGRAPHY; PRIORITY JOURNAL; RISK REDUCTION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; WOUND CLOSURE;

EID: 77649164319     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60139-0     Document Type: Note

References (8)

1. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest 133 (2008) 381S-453S
2. Fareed J., Hoppensteadt D.A., Fareed D., et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 34 (2008) 58-73
3. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P., and ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375 (2010) 807-815
4. Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., and Portman R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361 (2009) 594-604
5. Douketis J.D., Arneklev K., Goldhaber S.Z., Spandorfer J., Halperin F., and Horrow J. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med 166 (2006) 853-859
6. Schulman S., and Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005) 692-694
7. Straus S.E. Individualizing treatment decisions: the likelihood of being helped or harmed. Eval Health Prof 25 (2002) 210-224
8. Hull R.D., Yusen R.D., and Bergqvist D. State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 15 (2009) 377-388